<DOC>
	<DOC>NCT01768039</DOC>
	<brief_summary>Two hundred and forty patients with multiple sclerosis who met the study criteria will be enrolled in this randomized double blind placebo-controlled clinical trial. They will randomly assigned to placebo or vitamin D treatment group. The total time of study is 52 weeks and the vitamin D group will be treated by weekly 50000 International unit(IU) vitamin D, while the other group will receive weekly placebo. The annual relapse rate and EDSS will be compared at baseline, month 6 and 12.</brief_summary>
	<brief_title>Vitamine D in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>BMI:1830kg/m2 caucasian race Relapsing remitting multiple sclerosis treatment with interferon beta Recent vitamin D supplement therapy Restricted fat diet nephrolithiasis in recent 5 years Past history of hyperparathyroidism, sarcoidosis, cancer Past history of hepatic disease Past history of gastrointestinal disease Past history of mycobacterial infection Past history of hypercalcemia and hypercalciuria serum creatinine&gt;1.5 Smoking, drug abuse and corticosteroid therapy in recent year treatment with thiazides or other drugs that inhibit vitamin D absorption Disease attack in recent 2 months Serum Ca&gt;2.6mm0l/L Serum 25(OH)D&gt;85mmol/L hypersensitivity to cholecalciferol Past history of heart disease Major depression Uncontrolled hypertension (BP&gt;180/110) Immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>EDSS</keyword>
	<keyword>ARR</keyword>
</DOC>